Canada markets close in 4 hours 47 minutes

Evofem Biosciences, Inc. (EVFM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0134-0.0005 (-3.60%)
As of 10:50AM EDT. Market open.

Evofem Biosciences, Inc.

7770 Regents Roas
Suite 113-618
San Diego, CA 92122
United States
858 550 1900

Full Time Employees37

Key Executives

NameTitlePayExercisedYear Born
Ms. Saundra PelletierInterim Chair, President & CEO1.52MN/A1970
Ms. Ivy ZhangCFO & Secretary438.85kN/A1979
Ms. Amy RaskopfSenior Vice President of Investor RelationsN/AN/AN/A
Kathy Gallo-DoyleVice President of SalesN/AN/AN/A
Ms. Rachael Hildebrandt P.H.R.Head of Human ResourcesN/AN/AN/A
Ms. Ellen ThomasChief of StaffN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Corporate Governance

Evofem Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.